Atlas of Genetics and Cytogenetics in Oncology and Haematology
TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b, decoy)
| Identity |
| Other names | DCR3 (decoy receptor 3) |
| DJ583P15.1.1 | |
| M68 | |
| TR6 (TNF receptor family member 6) | |
| Hugo | TNFRSF6B |
| Location | 20q13.3 |
| DNA/RNA |
 | |
| Description | DNA sequence is located on chromosome 20. Transcription consists of 7 exons and 6 introns, spanning 3.6kb. A shorter transcription variance (M68E) has been identified, and is transcribed from 3 exons and 2 introns spanning 1.9kb as illustrated above. The difference occurs at the 5' untranslated region, but the two transcripts encode the same isoform. Mice do not have a gene orthologue to human TNFRSF6B. TNFRSF68B mRNA in Northen blot presents as a 1.2-knt band. |
| Protein |
 | |
| A) Domains and Motifs. B) TNFRSF6B X-ray crystography | |
| Description | TNFRSF6B protein is 300-amino acid long, and has a molecular weight of 35 kD. Although TNFRSF6B belongs to the TNFR superfamily, it lacks the transmembrane and cytosolic domains in its sequence, and is a secreted protein. It contains 4 TNFR cystein-rich regions, as illustrated above. TNFRSF6B can be easily cleaved between Arg218 and Ala219 in biological fluids and solutions. It has thus a very short (about 20 min) half-life in serum and in vivo. Mutation of arginine residue at position 218 to glutamine makes TNFRSF6B resistant to proteolysis, and significantly prolongs its half-life. TNFRSF6B can bind to the TNF family members FasL, LIGHT and TL1A. It does not bind to other known TNF family members. Human TNFRSF6B can bind to mouse FasL, LIGHT and TL1A. This allows human DcR3/TNFRSF6B to function in mouse models both in vitro and in vivo. The role of TNFRSF6B in apoptosis is obvious. FasL is a well-known molecule involved in apoptosis. LIGHT is a ligand for HVEM and LTbetaR, in addition to being a ligand for TNFRSF6B. LIGHT can induce apoptosis in cells expressing both HVEM and LTbetaR, or LTbetaR alone. TL1A, a member of the TNF family, can evoke apoptosis via its receptor, DR3. Consequently, the interaction of TNFRSF6B with FasL, LIGHT, and TL1A blocks apoptosis mediated by Fas, HVEM, LTbetaR and DR3. |
| Expression | Normal tissue and cells express low-level TNFRSF6B, and healthy individuals have near-background serum TNFRSF6B levels. About 60% of malignant tumors of various tissue origins overexpress TNFRSF6B, and these patients have elevated serum TNFRSF6B levels. Serum TNFRSF6B levels of tumor patients are positively correlated to the degree of tumor malignancy and status of metastasis. It is hypothesized that malignant tumor cells secrete TNFRSF6B as a way to achieve survival advantage by blocking multiple apoptosis pathways. Hepatocytes in liver cirrhosis have augmented TNFRSF6B expression and patients with liver cirrhosis have increased serum TNFRSF6B levels. TNFRSF6B expression is low in resting T cells but is augmented in activated T cells, which probably represents a fine-tuning mechanism to balance the need for clonal expansion and subsequent massive activation-induced T cell death. About 40% of systemic lupus erythematosus patients have elevated serum TNFRSF6B levels. TNFRSF6B expression in rheumatoid arthritis fibroblast-like synoviocytes is increased by TNFalpha |
| Localisation | TNFRSF6B is a secreted protein, and is thus detected in body fluids. However, it can also be detected in cytoplasm before it is secreted. |
| Function | As TNFRSF6B can block ligands from interacting with Fas, HVEM, LTbetaR, and DR3, all of which mediate apoptosis, it is thus can effectively inhibit apoptosis in many cell types. It is believed that many types of malignant tumors gain survival advantage by secreting TNFRSF6B which blocks tumor cell apoptosis. Syngeneic islets transplanted to diabetes recipients survive better in the presence of administered exogenous human TNFRSF6B, due to the blockage of FasL-, LIGHT- and TL1A-triggered islets apoptosis. Transgenic expression of human TNFRSF6B in NOD mouse islets reduces diabetes pathogenesis, again, due to anti-apoptotic effect of TNFRSF6B. The forward signaling from FasL to Fas, and from LIGHT to HVEM can provide costimulation signals to resting T cells. Blocking of these two signaling pathways reduces T cell responses to antigens. As LIGHT and FasL, although being ligands, are also transmembrane proteins, and are capable of reversely transducing costimulating signals into T cells, TNFRSF6B can also block such reverse signaling. The end result is that TNFRSF6B can reduce several costimulation pathways in T cells and inhibit T cell immune responses, such as cytokine secretion and proliferation in vitro, and cardiac allograft rejection in vivo in mouse models. When human TNFRSF6B is linked to a transmembrane domain and is expressed on the mouse tumor cell surface, it can effectively trigger T cell costimulation via LIGHT and FasL reverse signaling, and cause effective tumor vaccination in mouse models. When human TNFRSF6B is transgenically expressed in mice, it causes a systemic lupus erythrematosus-like syndrome. The expression of TNFRSF6B in bone marrow-derived cells is sufficient to induce this phenotype. Recombinant human TNFRSF6B ameliorates an autoimmune crescentic glomerulonephritis model in mice. TNFRSF6B can influence dendritic cells which in turn drive T cells to differentiate into Th2 cells. TNFRSF6B can inhibit actin polymerization of T cells upon mitogen stimulation, and repress T-cell pseudopodium formation, which is known to be important for cell-cell interaction. As a consequence, T-cell aggregation after activation is suppressed by either soluble or solid phase TNFRSF6B. Human T cells pretreated with soluble or solid-phase TNFRSF6B are compromised in migration in vitro and in vivo toward CXCL12. Mechanistically, a small GTPase Cdc42 fails to be activated after TNFRSF6B pretreatment of human T cells, and further downstream, p38 mitogen-activated protein kinase activation, actin polymerization, and pseudopodium formation are all down-regulated in the treated T cells. Phagocytic activity toward immune complexes and apoptotic bodies as well as the production of free radicals and proinflammatory cytokines in response to lipopolysaccharide are impaired in TNFRSF6B-treated macrophages. |
| Mutations |
| Note | Not reported yet. |
| Implicated in |
| Entity | Malignant tumors |
| Disease | Oncogenesis TNFRSF6B is overexpressed in about 60% of various malignant tumors. Its anti-apoptotic effect provides the tumors a survival advantage, and its role in reducing T cell costimulation favors tumor evasion from the immune surveillance. No TNFRSF6B gene amplification in tumors has been identified. Diagnosis and prognosis TNFRSF6B in sera or tumor can be used as a parameter for tumor diagnosis and prognosis. The degree of tumor malignancy is correlated to TNFRSF6B levels. When a TNFRSF6B-expressing tumor is resected, serum TNFRSF6B levels will decrease to near-zero level. The re-arising of serum TNFRSF6B in such patients will indicate tumor reoccurrence. Therapeutics When TNFRSF6B is anchored on tumor cell surface, it can increase the antigenicity of the tumor, and such TNFRSF6B-expressing tumors can be used as tumor vaccine. |
| Entity | Systemic lupus erythematosus (SLE) |
| Disease | Pathogenesis About 50% of SLE patients have elevated serum TNFRSF6B levels, and the levels augment during SLE flare-up. In animal models, human TNFRSF6B overexpression in mouse cells of hematopoietic origin leads to a SLE-like syndrome, suggesting a pathogenic role of TNFRSF6B in SLE. Diagnosis Serum TNFRSF6B can be used as a diagnostic parameter for SLE and SLE disease activity. Therapeutics Due to the pathogenic effect of TNFRSF6B on SLE, it is speculated that neutralizing TNFRSF6B might have therapeutic effect on a subpopulation of SLE patients, who are serum TNFSF6B positive. |
| Entity | Islet primary nonfunction during islet transplantation |
| Disease | Therapeutics Due to the anti-apoptotic effect of TNFRSF6B, it can effectively protect islets from apoptosis during their isolation, transportation, and primary non-function after transplantation. |
| External links |
| Bibliography |
| Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. |
| Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A |
| Nature. 1998 ; 396 (6712) : 699-703. |
| PMID 9872321 |
| A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. |
| Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS |
| The Journal of biological chemistry. 1999 ; 274 (20) : 13733-13736. |
| PMID 10318773 |
| Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. |
| Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT |
| Proceedings of the National Academy of Sciences of the United States of America. 2000 ; 97 (3) : 1230-1235. |
| PMID 10655513 |
| Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. |
| Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M |
| Cancer letters. 2000 ; 160 (1) : 89-97. |
| PMID 11098089 |
| Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. |
| Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Kita S, Ueki A |
| Clinical and experimental immunology. 2000 ; 119 (2) : 323-327. |
| PMID 10632670 |
| Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. |
| Maeda T, Hao C, Tron VA |
| Journal of cutaneous medicine and surgery. 2001 ; 5 (4) : 294-298. |
| PMID 11907838 |
| Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. |
| Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bˆ§hr M, Ohgaki H, Ashkenazi A, Weller M |
| Cancer research. 2001 ; 61 (6) : 2759-2765. |
| PMID 11289159 |
| Modulation of T-cell responses to alloantigens by TR6/DcR3. |
| Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, Li Y, Moore PA, Wu J |
| The Journal of clinical investigation. 2001 ; 107 (11) : 1459-1468. |
| PMID 11390428 |
| Modulation of dendritic cell differentiation and maturation by decoy receptor 3. |
| Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL |
| Journal of immunology (Baltimore, Md. : 1950). 2002 ; 168 (10) : 4846-4853. |
| PMID 11994433 |
| DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. |
| Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C |
| International journal of cancer. Journal international du cancer. 2002 ; 102 (3) : 254-257. |
| PMID 12397645 |
| The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. |
| Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y |
| Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2002 ; 5 (2) : 61-68. |
| PMID 12111580 |
| A TNF family member LIGHT transduces costimulatory signals into human T cells. |
| Wan X, Zhang J, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P, Wu J |
| Journal of immunology (Baltimore, Md. : 1950). 2002 ; 169 (12) : 6813-6821. |
| PMID 12471113 |
| Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. |
| Bridgham JT, Johnson AL |
| Biochemical and biophysical research communications. 2003 ; 307 (4) : 956-961. |
| PMID 12878204 |
| Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. |
| Shi G, Wu Y, Zhang J, Wu J |
| Journal of immunology (Baltimore, Md. : 1950). 2003 ; 171 (7) : 3407-3414. |
| PMID 14500635 |
| Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. |
| Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E, Ito D, Kami K, Mori T, Fujimoto K, Doi R, Imamura M |
| International journal of cancer. Journal international du cancer. 2003 ; 106 (1) : 17-25. |
| PMID 12794752 |
| DcR3/TR6 modulates immune cell interactions. |
| Wan X, Shi G, Semenuk M, Zhang J, Wu J |
| Journal of cellular biochemistry. 2003 ; 89 (3) : 603-612. |
| PMID 12761893 |
| Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. |
| Wortinger MA, Foley JW, Larocque P, Witcher DR, Lahn M, Jakubowski JA, Glasebrook A, Song HY |
| Immunology. 2003 ; 110 (2) : 225-233. |
| PMID 14511236 |
| Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. |
| Wroblewski VJ, McCloud C, Davis K, Manetta J, Micanovic R, Witcher DR |
| Drug metabolism and disposition: the biological fate of chemicals. 2003 ; 31 (4) : 502-507. |
| PMID 12642478 |
| Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. |
| Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE |
| Biochemical pharmacology. 2003 ; 65 (4) : 657-667. |
| PMID 12566095 |
| DcR3/TR6 effectively prevents islet primary nonfunction after transplantation. |
| Wu Y, Han B, Luo H, Roduit R, Salcedo TW, Moore PA, Zhang J, Wu J |
| Diabetes. 2003 ; 52 (9) : 2279-2286. |
| PMID 12941767 |
| Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. |
| Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J |
| International journal of cancer. Journal international du cancer. 2003 ; 105 (5) : 724-732. |
| PMID 12740925 |
| Modulation of macrophage differentiation and activation by decoy receptor 3. |
| Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL |
| Journal of leukocyte biology. 2004 ; 75 (3) : 486-494. |
| PMID 14657214 |
| Quantification and detection of DcR3, a decoy receptor in TNFR family. |
| Chen J, Zhang L, Kim S |
| Journal of immunological methods. 2004 ; 285 (1) : 63-70. |
| PMID 14871535 |
| Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. |
| Gill RM, Hunt JS |
| The American journal of pathology. 2004 ; 165 (1) : 309-317. |
| PMID 15215185 |
| Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. |
| Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, Chio CC, Hsieh SL |
| Experimental cell research. 2004 ; 292 (2) : 241-251. |
| PMID 14697332 |
| Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery. |
| Hwang SL, Lin CL, Cheng CY, Lin FA, Lieu AS, Howng SL, Lee KS |
| The Kaohsiung journal of medical sciences. 2004 ; 20 (3) : 124-127. |
| PMID 15124896 |
| Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. |
| Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B |
| Infection and immunity. 2004 ; 72 (1) : 89-93. |
| PMID 14688085 |
| Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. |
| Sung HH, Juang JH, Lin YC, Kuo CH, Hung JT, Chen A, Chang DM, Chang SY, Hsieh SL, Sytwu HK |
| The Journal of experimental medicine. 2004 ; 199 (8) : 1143-1151. |
| PMID 15078896 |
| Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. |
| Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW |
| Cancer research. 2004 ; 64 (3) : 1122-1129. |
| PMID 14871847 |
| Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. |
| Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW |
| Cell death and differentiation. 2004 ; 11 Suppl 1 : S97-107. |
| PMID 15002040 |
| Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. |
| Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ |
| The Journal of biological chemistry. 2004 ; 279 (42) : 44211-44218. |
| PMID 15475369 |
| Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. |
| Wu SF, Liu TM, Lin YC, Sytwu HK, Juan HF, Chen ST, Shen KL, Hsi SC, Hsieh SL |
| Journal of leukocyte biology. 2004 ; 75 (2) : 293-306. |
| PMID 14634066 |
| Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. |
| Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y |
| Acta neuropathologica. 2005 ; 109 (3) : 294-298. |
| PMID 15627206 |
| Attenuation of Th1 response in decoy receptor 3 transgenic mice. |
| Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL |
| Journal of immunology (Baltimore, Md. : 1950). 2005 ; 175 (8) : 5135-5145. |
| PMID 16210617 |
| Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. |
| Kim S, Fotiadu A, Kotoula V |
| Clinical immunology (Orlando, Fla.). 2005 ; 115 (3) : 286-294. |
| PMID 15893696 |
| Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. |
| Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY |
| American journal of clinical pathology. 2005 ; 124 (2) : 282-287. |
| PMID 16040301 |
| Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. |
| Shen HW, Gao SL, Wu YL, Peng SY |
| World journal of gastroenterology : WJG. 2005 ; 11 (38) : 5926-5930. |
| PMID 16273601 |
| Tumor vaccine based on cell surface expression of DcR3/TR6. |
| Shi G, Mao J, Yu G, Zhang J, Wu J |
| Journal of immunology (Baltimore, Md. : 1950). 2005 ; 174 (8) : 4727-4735. |
| PMID 15814697 |
| Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. |
| Yang CR, Hsieh SL, Ho FM, Lin WW |
| Journal of immunology (Baltimore, Md. : 1950). 2005 ; 174 (3) : 1647-1656. |
| PMID 15661928 |
| The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. |
| Chang YC, Chan YH, Jackson DG, Hsieh SL |
| Journal of immunology (Baltimore, Md. : 1950). 2006 ; 176 (1) : 173-180. |
| PMID 16365408 |
| Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. |
| Fayad R, Brand MI, Stone D, Keshavarzian A, Qiao L |
| European journal of immunology. 2006 ; 36 (8) : 2215-2222. |
| PMID 16856205 |
| Alterations of Fas and Fas-related molecules in patients with silicosis. |
| Otsuki T, Miura Y, Nishimura Y, Hyodoh F, Takata A, Kusaka M, Katsuyama H, Tomita M, Ueki A, Kishimoto T |
| Experimental biology and medicine (Maywood, N.J.). 2006 ; 231 (5) : 522-533. |
| PMID 16636300 |
| Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome. |
| Han B, Moore PA, Wu J, Luo H |
| Arthritis and rheumatism. 2007 ; 56 (11) : 3748-3758. |
| PMID 17968950 |
| Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. |
| Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, Hashiramoto A, Kurosaka M, Shiozawa S, Doita M |
| Arthritis and rheumatism. 2007 ; 56 (4) : 1067-1075. |
| PMID 17393415 |
| Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. |
| Ho CH, Hsu CF, Fong PF, Tai SK, Hsieh SL, Chen CJ |
| Journal of virology. 2007 ; 81 (9) : 4837-4847. |
| PMID 17301127 |
| Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. |
| Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A |
| Journal of the American Society of Nephrology : JASN. 2007 ; 18 (9) : 2473-2485. |
| PMID 17687076 |
| Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. |
| Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW |
| Gynecologic oncology. 2007 ; 106 (1) : 112-118. |
| PMID 17490732 |
| Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. |
| Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL, Fu WM |
| The Journal of biological chemistry. 2007 ; 282 (4) : 2346-2354. |
| PMID 17099218 |
| Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). |
| You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL |
| Blood. 2008 ; 111 (3) : 1480-1488. |
| PMID 18006694 |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| Contributor(s) |
| Written | 12-2007 | Jiangping Wu, Bing Han |
| CHUM Research Center, University of Montreal, Canada |
| Citation |
| This paper should be referenced as such : |
| Wu J, Han B . TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b, decoy). Atlas Genet Cytogenet Oncol Haematol. December 2007 . URL : http://AtlasGeneticsOncology.org/Genes/TNFRSF6BID42628ch20q13.html |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Wed Jul 2 08:27:43 2008 |
For comments and suggestions or contributions, please contact us